每經AI快訊，南(nan)模(mo)生物（SH 688265，收盤價：49.36元(yuan)）3月(yue)(yue)14日(ri)(ri)(ri)(ri)晚間(jian)發布公(gong)(gong)(gong)告(gao)(gao)(gao)稱，截至本(ben)(ben)公(gong)(gong)(gong)告(gao)(gao)(gao)披露之(zhi)(zhi)日(ri)(ri)(ri)(ri)，上海(hai)南(nan)方模(mo)式生物科(ke)技股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)有限(xian)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)東(dong)(dong)北(bei)京康(kang)君(jun)寧元(yuan)股(gu)(gu)(gu)(gu)(gu)(gu)權(quan)投(tou)(tou)資(zi)(zi)合(he)伙(huo)(huo)企業(ye)（有限(xian)合(he)伙(huo)(huo)）持(chi)(chi)(chi)有公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)(yue)585萬股(gu)(gu)(gu)(gu)(gu)(gu)，占公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的7.5%；相關(guan)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)來(lai)源于(yu)公(gong)(gong)(gong)司(si)(si)(si)首次公(gong)(gong)(gong)開發行前取(qu)得(de)的股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)，且(qie)已(yi)于(yu)2022年12月(yue)(yue)28日(ri)(ri)(ri)(ri)起解除(chu)限(xian)售并上市流通。股(gu)(gu)(gu)(gu)(gu)(gu)東(dong)(dong)康(kang)君(jun)寧元(yuan)因自(zi)身資(zi)(zi)金需求(qiu)，擬通過(guo)(guo)(guo)(guo)(guo)集中競(jing)價或大宗交(jiao)(jiao)易(yi)方式合(he)計減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)其所(suo)持(chi)(chi)(chi)有的公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)約(yue)(yue)(yue)234萬股(gu)(gu)(gu)(gu)(gu)(gu)，即不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的3%。其中，以集中競(jing)價交(jiao)(jiao)易(yi)方式減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)，減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)期(qi)間(jian)為(wei)(wei)(wei)自(zi)本(ben)(ben)公(gong)(gong)(gong)告(gao)(gao)(gao)披露之(zhi)(zhi)日(ri)(ri)(ri)(ri)起15個(ge)(ge)交(jiao)(jiao)易(yi)日(ri)(ri)(ri)(ri)后的6個(ge)(ge)月(yue)(yue)內(nei)(nei)，減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)數量(liang)(liang)不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)約(yue)(yue)(yue)156萬股(gu)(gu)(gu)(gu)(gu)(gu)，即不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的2%；以大宗交(jiao)(jiao)易(yi)方式減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)，減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)期(qi)間(jian)為(wei)(wei)(wei)自(zi)本(ben)(ben)公(gong)(gong)(gong)告(gao)(gao)(gao)披露之(zhi)(zhi)日(ri)(ri)(ri)(ri)起3個(ge)(ge)交(jiao)(jiao)易(yi)日(ri)(ri)(ri)(ri)后的6個(ge)(ge)月(yue)(yue)內(nei)(nei)，減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)數量(liang)(liang)不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)約(yue)(yue)(yue)234萬股(gu)(gu)(gu)(gu)(gu)(gu)，即不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的3%。康(kang)君(jun)寧元(yuan)為(wei)(wei)(wei)已(yi)在中國證券(quan)投(tou)(tou)資(zi)(zi)基(ji)金業(ye)協會(hui)完(wan)成(cheng)備案的私募基(ji)金，并已(yi)向(xiang)中國證券(quan)投(tou)(tou)資(zi)(zi)基(ji)金業(ye)協會(hui)成(cheng)功申請了創業(ye)投(tou)(tou)資(zi)(zi)基(ji)金股(gu)(gu)(gu)(gu)(gu)(gu)東(dong)(dong)的減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)政(zheng)策，其投(tou)(tou)資(zi)(zi)期(qi)限(xian)不(bu)(bu)(bu)(bu)滿36個(ge)(ge)月(yue)(yue)，減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)比例(li)遵循《上市公(gong)(gong)(gong)司(si)(si)(si)創業(ye)投(tou)(tou)資(zi)(zi)基(ji)金股(gu)(gu)(gu)(gu)(gu)(gu)東(dong)(dong)減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)的特別規(gui)定(ding)(ding)》《上海(hai)證券(quan)交(jiao)(jiao)易(yi)所(suo)上市公(gong)(gong)(gong)司(si)(si)(si)創業(ye)投(tou)(tou)資(zi)(zi)基(ji)金股(gu)(gu)(gu)(gu)(gu)(gu)東(dong)(dong)減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)實(shi)施(shi)細則(ze)》有關(guan)規(gui)定(ding)(ding)，連(lian)續(xu)90個(ge)(ge)自(zi)然日(ri)(ri)(ri)(ri)內(nei)(nei)通過(guo)(guo)(guo)(guo)(guo)集中競(jing)價交(jiao)(jiao)易(yi)減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)數量(liang)(liang)不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的1%，連(lian)續(xu)90個(ge)(ge)自(zi)然日(ri)(ri)(ri)(ri)內(nei)(nei)通過(guo)(guo)(guo)(guo)(guo)大宗交(jiao)(jiao)易(yi)減(jian)(jian)(jian)(jian)持(chi)(chi)(chi)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)數量(liang)(liang)不(bu)(bu)(bu)(bu)超(chao)過(guo)(guo)(guo)(guo)(guo)公(gong)(gong)(gong)司(si)(si)(si)總(zong)(zong)股(gu)(gu)(gu)(gu)(gu)(gu)本(ben)(ben)的2%。

2021年1至12月份(fen)，南模生物的營業(ye)收入構成為：科學(xue)研究和技術服務業(ye)占比99.41%。

南(nan)模生物的董事長是費(fei)儉(jian)，男，58歲，學歷(li)背景為博士(shi)；總(zong)經理是王明俊(jun)，男，51歲，學歷(li)背景為碩士(shi)。

截至發稿，南模(mo)生物市值(zhi)為38億(yi)元。

道(dao)達號（daoda1997）“個股趨勢”提醒：
1. 近30日內無機構對南模生物進行調研。
更(geng)多(duo)個股趨(qu)勢信(xin)息，請搜索(suo)微(wei)信(xin)公(gong)眾號“道達號”，回復“查(cha)(cha)詢”，領取免費查(cha)(cha)詢權限(xian)！

每經頭條（nbdtoutiao）——

(記者 尹華祿)

免(mian)責聲明(ming)：本文內容與(yu)數據僅供參考，不構(gou)成投資建(jian)議，使用前請核(he)實(shi)。據此操作，風險自擔。